Candelaria Gomez-Manzano, MD

Departments of Neuro-Oncology and Genetics, MD Anderson Cancer Center, Houston, Texas, USA

Candelaria Gomez-Manzano received her MD degree from University of Barcelona, Spain, and completed the residency program in clinical Neurology in Hospital del Mar, Barcelona, Spain. After a postdoctoral training in experimental Neuro-Oncology at MD Anderson Cancer Center, Houston, TX, USA, she stayed at MD Anderson as faculty in the Department of Neuro-Oncology with a join appointment in the Department of Genetics. Currently she holds the position of Associate professor at MD Anderson Cancer Center. The research in her laboratory is focused on understanding the cause of resistance to therapies. Her group pioneered the studies on the role of inflammatory cells and tumor microenvironment in the response of malignant gliomas to therapies, specifically by studying the role of Tie2 in radioresistance. She has co-discovered Delta-24-RGD, an oncolytic adenovirus generated for glioma therapy. This agent is being used in Phase I clinical trials in USA, Canada, and Europe for patients with malignant gliomas. She has published more than 100 peer-reviewed manuscripts, invited reviews, editorials, and book chapters. In addition, D. Gomez-Manzano serves as Director of Education in the Brain Tumor Research Program and she is member faculty in the Cancer Biology Program of the Graduate School of Biomedical Sciences, Houston, TX, USA. She served as ad-hoc reviewer in NIH study sections. She is an investigator of the Brain Cancer SPORE at her institution, and she is currently funded by the NIH, US DOD, and CPRIT mechanisms.